Neuro-Oncology News

The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier, study results showed.

University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.

The FDA announced several regulatory actions the past few weeks.

The FDA approved dabrafenib with trametinib for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy.

Vorasidenib conferred statistically significant and clinically meaningful improvements in PFS and time to next intervention for patients with residual or recurrent IDH-mutant low-grade glioma, according to the agent’s manufacturer.

An artificial intelligence algorithm that uses computational analysis to identify possible therapeutic targets for glioblastoma multiforme and other types of cancer could have broad treatment implications, according to its developers.

When administering chemotherapy to a patient with recurrent glioblastoma, physicians must overcome the blood-brain barrier, an immunologic feature of the central nervous system.

The FDA announced several regulatory actions the past few weeks.

The economic cost of cancer worldwide from 2020 to 2050 will be $25.2 trillion in international dollars, according to results of a decision analytical modeling study published in JAMA Oncology.

The FDA announced several regulatory actions the past few weeks.